Proton pump inhibitors induced fungal dysbiosis in patients with gastroesophageal reflux disease

被引:5
作者
Shi, Yichao [1 ,2 ]
Li, Jianfeng [2 ]
Cai, Shuntian [2 ]
Zhao, Hong [3 ]
Zhao, Huijun [2 ]
Sun, Gang [2 ]
Yang, Yunsheng [2 ,4 ]
机构
[1] Peking Univ, Aerosp Ctr Hosp, Dept Gastroenterol, Aerosp Sch Clin Med, Beijing, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Gastroenterol & Hepatol, Beijing, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Neurol, Beijing, Peoples R China
[4] Chinese Peoples Liberat Army Gen Hosp, Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China
来源
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY | 2023年 / 13卷
关键词
gastroesophageal reflux disease; proton pump inhibitor; fecal mycobiota; Candida; gastric mucosal mycobiota; LONG-TERM USE; CANDIDA-ALBICANS; COMMENSAL FUNGI; THERAPY; MICROBIOME; RISK; INFLAMMATION; PROPHYLAXIS; MEDICATION; ESOPHAGUS;
D O I
10.3389/fcimb.2023.1205348
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Gut mycobiota inhabits human gastrointestinal lumen and plays a role in human health and disease. We investigated the influence of proton pump inhibitors (PPIs) on gastric mucosal and fecal mycobiota in patients with gastroesophageal reflux diseases (GERD) by using Internal Transcribed Spacer 1 sequencing. A total of 65 participants were included, consisting of the healthy control (HC) group, GERD patients who did not use PPIs (nt-GERD), and GERD patients who used PPIs, which were further divided into short-term (s-PPI) and long-term PPI user (l-PPI) groups based on the duration of PPI use. The alpha diversity and beta diversity of gastric mucosal mycobiota in GERD patients with PPI use were significantly different from HCs, but there were no differences between s-PPI and l-PPI groups. LEfSe analysis identified Candida at the genus level as a biomarker for the s-PPI group when compared to the nt-GERD group. Meanwhile, Candida, Nothojafnea, Rhizodermea, Ambispora, and Saccharicola were more abundant in the l-PPI group than in the nt-GERD group. Furthermore, colonization of Candida in gastric mucosa was significantly increased after PPI treatment. However, there was no significant difference in Candida colonization between patients with endoscopic esophageal mucosal breaks and those without. There were significant differences in the fecal mycobiota composition between HCs and GERD patients regardless whether or not they used PPI. As compared to nt-GERD patient samples, there was a high abundance of Alternaria, Aspergillus, Mycenella, Exserohilum, and Clitopilus in the s-PPI group. In addition, there was a significantly higher abundance of Alternaria, Aspergillus, Podospora, Phallus, and Monographella in the l-PPI group than nt-GERD patients. In conclusion, our study indicates that dysbiosis of mycobiota was presented in GERD patients in both gastric mucosal and fecal mycobiota. PPI treatment may increase the colonization of Candida in the gastric mucosa in GERD patients.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] On-demand therapy for gastroesophageal reflux disease: Are current proton pump inhibitors good candidates?
    Goh, Khean-Lee
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : S115 - S118
  • [42] Systematic review:Laparoscopic fundoplication for gastroesophageal reflux disease in partial responders to proton pump inhibitors
    Lars Lundell
    Martin Bell
    Magnus Ruth
    World Journal of Gastroenterology, 2014, 20 (03) : 804 - 813
  • [43] Anti-reflux Surgery Versus Proton Pump Inhibitors for Severe Gastroesophageal Reflux Disease: A Cost-Effectiveness Study in Korea
    Park, Susan
    Park, Sungsoo
    Park, Joong-Min
    Ryu, Soorack
    Hwang, Jinseub
    Kwon, Jin-Won
    Seo, Kyung Won
    JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2020, 26 (02) : 215 - 223
  • [44] Relationship between long-term use of proton pump inhibitor (PPI) and hypomagnesemia in patients with gastroesophageal reflux disease
    Arj, Abbas
    Takizadeh, Zeinab Ghale
    Gilassi, Hamidreza
    Razavizadeh, Mohsen
    CASPIAN JOURNAL OF INTERNAL MEDICINE, 2022, 13 (01) : 107 - 112
  • [45] Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease
    Yadlapati, Rena
    Delay, Kelli
    MEDICAL CLINICS OF NORTH AMERICA, 2019, 103 (01) : 15 - +
  • [46] Proton Pump Inhibitor Prescriptions and Subsequent Use in US Veterans Diagnosed with Gastroesophageal Reflux Disease
    Gawron, Andrew J.
    Pandolfino, John E.
    Miskevics, Scott
    LaVela, Sherri L.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2013, 28 (07) : 930 - 937
  • [47] Symptom Predictability in Gastroesophageal Reflux Disease and Role of Proton Pump Inhibitor Test
    Estores, David S.
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2014, 43 (01) : 27 - +
  • [48] Prospective Evaluation of Duodenogastroesophageal Reflux in Gastroesophageal Reflux Disease Patients Refractory to Proton Pump Inhibitor Therapy
    Kunsch, S.
    Neesse, A.
    Linhart, T.
    Nell, C.
    Gress, T. M.
    Ellenrieder, V.
    DIGESTION, 2012, 86 (04) : 315 - 322
  • [49] Effects of rikkunshito on quality of life in patients with gastroesophageal reflux disease refractory to proton pump inhibitor therapy
    Kawai, Takashi
    Hirayama, Yoji
    Oguchi, Aiko
    Ishii, Fumi
    Matushita, Masanao
    Kitayama, Naoya
    Morishita, Shinji
    Hiratsuka, Noboru
    Ohata, Ken
    Konishi, Hiroyuki
    Kishino, Maiko
    Nakamura, Shinichi
    JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION, 2017, 60 (02) : 143 - 145
  • [50] Protective Effect of Proton Pump Inhibitor for Survival in Patients with Gastroesophageal Reflux Disease and Idiopathic Pulmonary Fibrosis
    Lee, Chang Min
    Lee, Dong Ho
    Ahn, Byung Kyu
    Hwang, Jae Jin
    Yoon, Hyuk
    Shin, Cheol Min
    Park, Young Soo
    Kim, Nayoung
    JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2016, 22 (03) : 444 - 451